Search details
1.
Safety and efficacy of off-label bulevirtide monotherapy in patients with HDV with decompensated Child-B cirrhosis-A real-world case series.
Hepatology
; 2024 Mar 13.
Article
in English
| MEDLINE | ID: mdl-38478755
2.
Quantification of circulating HBV RNA expressed from intrahepatic cccDNA in untreated and NUC treated patients with chronic hepatitis B.
Gut
; 73(4): 659-667, 2024 Mar 07.
Article
in English
| MEDLINE | ID: mdl-37879886
3.
Development and validation of a scoring system to predict response to obeticholic acid in primary biliary cholangitis.
Clin Gastroenterol Hepatol
; 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38782175
4.
Quantification of serum HDV RNA by Robogene 2.0 in HDV patients is significantly influenced by the extraction methods.
Liver Int
; 44(3): 831-837, 2024 Mar.
Article
in English
| MEDLINE | ID: mdl-38247385
5.
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics.
J Hepatol
; 2023 Jan 03.
Article
in English
| MEDLINE | ID: mdl-36931396
6.
Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B.
J Hepatol
; 79(1): 50-60, 2023 07.
Article
in English
| MEDLINE | ID: mdl-36893853
7.
Bulevirtide-based treatment strategies for chronic hepatitis delta: A review.
J Viral Hepat
; 30 Suppl 1: 26-32, 2023 04.
Article
in English
| MEDLINE | ID: mdl-36740364
8.
Bulevirtide for patients with compensated chronic hepatitis delta: A review.
Liver Int
; 43 Suppl 1: 80-86, 2023 08.
Article
in English
| MEDLINE | ID: mdl-35942695
9.
Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis.
Gut
; 71(3): 593-604, 2022 03.
Article
in English
| MEDLINE | ID: mdl-33741640
10.
Incidence of liver- and non-liver-related outcomes in patients with HCV-cirrhosis after SVR.
J Hepatol
; 76(2): 302-310, 2022 02.
Article
in English
| MEDLINE | ID: mdl-34592366
11.
Bulevirtide monotherapy for 48 weeks in patients with HDV-related compensated cirrhosis and clinically significant portal hypertension.
J Hepatol
; 77(6): 1525-1531, 2022 12.
Article
in English
| MEDLINE | ID: mdl-35973578
12.
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study: SIMPLE: Scoring Index to Monitor Progression of Low-risk Esophageal varices.
Am J Gastroenterol
; 117(11): 1816-1824, 2022 11 01.
Article
in English
| MEDLINE | ID: mdl-35973181
13.
Accuracy of Transient Elastography in Assessing Fibrosis at Diagnosis in Naïve Patients With Primary Biliary Cholangitis: A Dual Cut-Off Approach.
Hepatology
; 74(3): 1496-1508, 2021 09.
Article
in English
| MEDLINE | ID: mdl-33724515
14.
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy.
J Hepatol
; 74(4): 801-810, 2021 04.
Article
in English
| MEDLINE | ID: mdl-33220331
15.
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy.
Am J Gastroenterol
; 116(6): 1342-1344, 2021 06 01.
Article
in English
| MEDLINE | ID: mdl-33606382
16.
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting.
J Viral Hepat
; 28(3): 558-568, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33306247
17.
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs.
Hepatology
; 72(6): 1912-1923, 2020 12.
Article
in English
| MEDLINE | ID: mdl-32762045
18.
HDV RNA and liver disease progression: What do we know?
Hepatology
; 79(5): 983-985, 2024 May 01.
Article
in English
| MEDLINE | ID: mdl-38156968
19.
Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort.
Liver Int
; 40(4): 769-777, 2020 04.
Article
in English
| MEDLINE | ID: mdl-31970845
20.
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
J Hepatol
; 71(6): 1106-1115, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31433303